Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Why do we celebrate the International Clinical Trials Day?

What happened 271 ago? In May 1747, at a time when scurvy was rampant among sailors, James Lind, a pioneer of naval hygiene, conducted what is now considered to be the very first clinical trial. Lind, a surgeon mate on board HMS Salisbury, recruited twelve men into a study that investigated which acidic substances could cure scurvy (spoiler alert: it was citrus fruits).

Clinical Trials DaySince then, May 20th is widely celebrated as the International Clinical Trials Day. It is an occasion to highlight the importance of clinical trials, raise awareness of participation opportunities and discuss the process of volunteering – and members of Paediatrics’ Oxford Vaccine Group have been on board with the celebrations. Alongside leaflets and stickers, Annabel Coxon and Rebecca Beckley brought in a set of Lego people, which helped to explain how herd immunity works. The Lego game has been a hit with children and adults alike!

To get involved in the clinical trials run by Paediatrics, visit our recruiting page.

 

 

 

 

 

 

 

 

 

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.